Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models

Loading news article.

Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models | WAPE

Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models

Article summary

Related companies

Comments —